Active surveillance for localized prostate cancer - Current practices and recommendations

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 2352-2361

  Wu, Jennifer N ^a   Dall'Era, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Active surveillance; Localized; Prostate cancer; Review

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE COURSE; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOMES RESEARCH; PATIENT SELECTION; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; WATCHFUL WAITING;

HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 78650303018     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.227     Document Type: Review

References (56)

1. Jemal, A., Siegel, R., Xu, J., et al. (2010) Cancer Statistics, 2010. CA Cancer J. Clin. 60(5), 277.
2. Albertsen, P.C., Hanley, J.A., and Fine, J. (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293, 2095.
3. Johansson, J.E., Holmberg, L., Johansson, S., et al. (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277, 467.
4. Konety, B.R., Bird, V.Y., Deorah, S., et al. (2005) Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J. Urol. 174, 1785.
5. Delongchamps, N.B., Wang, C.Y., Chandan, V., et al. (2009) Pathological characteristics of prostate cancer in elderly men. J. Urol. 182, 927.
6. Sakr, W.A., Grignon, D.J., Crissman, J.D., et al. (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8, 439.
7. Draisma, G., Etzioni, R., Tsodikov, A., et al. (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl. Cancer Inst. 101, 374.
8. Schroder, F.H., Hugosson, J., Roobol, M.J., et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320.
9. rd, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310.
10. Cooperberg, M.R., Broering, J.M., and Carroll, P.R. (2010) Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28, 1117.
11. Shao, Y.H., Demissie, K., Shih, W., et al. (2009) Contemporary risk profile of prostate cancer in the United States. J. Natl. Cancer Inst. 101, 1280.
12. Shao, Y.H., Albertsen, P.C., Roberts, C.B., et al. (2010) Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch. Intern. Med. 170, 1256.
13. Wei, J.T., Dunn, R.L., Sandler, H.M., et al. (2002) Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J. Clin. Oncol. 20, 557.
14. Bailey, D.E., Jr., Wallace, M., and Mishel, M.H. (2007) Watching, waiting and uncertainty in prostate cancer. J. Clin. Nurs. 16, 734.
15. Galbraith, M.E., Ramirez, J.M., and Pedro, L.W. (2001) Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol. Nurs. Forum 28, 551.
16. Hedestig, O., Sandman, P.O., and Widmark, A. (2003) Living with untreated localized prostate cancer: a qualitative analysis of patient narratives. Cancer Nurs. 26, 55.
17. Wallace, M. (2003) Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol. Nurs. Forum 30, 303.
18. Cooperberg, M.R., Broering, J.M., Kantoff, P.W., et al. (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J. Urol. 178, S14.
19. Kattan, M.W., Eastham, J.A., Wheeler, T.M., et al. (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J. Urol. 170, 1792.
20. Roemeling, S., Roobol, M.J., Kattan, M.W., et al. (2007) Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer 110, 2218.
21. Cooperberg, M.R., Broering, J.M., and Carroll, P.R. (2009) Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J. Natl. Cancer Inst. 101, 878.
22. Epstein, J.I., Walsh, P.C., Carmichael, M., et al. (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271, 368.
23. Bastian, P.J., Mangold, L.A., Epstein, J.I., et al. (2004) Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101, 2001.
24. D'Amico, A.V., Whittington, R., Malkowicz, S.B., et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969.
25. Lieberfarb, M.E., Schultz, D., Whittington, R., et al. (2002) Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 53, 898.
26. Boorjian, S.A., Karnes, R.J., Rangel, L.J., et al. (2008) Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J. Urol. 179, 1354.
27. Kattan, M.W., Cuzick, J., Fisher, G., et al. (2008) Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 112, 69.
28. Coakley, F.V., Qayyum, A., and Kurhanewicz, J. (2003) Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J. Urol. 170, S69.
29. Shukla-Dave, A., Hricak, H., Kattan, M.W., et al. (2007) The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int. 99, 786.
30. Prando, A., Kurhanewicz, J., Borges, A.P., et al. (2005) Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236, 903.
31. Fradet, V., Kurhanewicz, J., Cowan, J.E., et al. (2010) Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 256, 176.
32. Conti, S.L., Dall'era, M., Fradet, V., et al. (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J. Urol. 181, 1628.
33. Mufarrij, P., Sankin, A., Godoy, G. et al. (2010) Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology 76, 689.
34. Berglund, R.K., Masterson, T.A., Vora, K.C., et al. (2008) Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J. Urol. 180, 1964.
35. Epstein, J.I., Walsh, P.C., and Carter, H.B. (2001) Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J. Urol. 166, 1688.
36. Patel, A.R. and Jones, J.S. (2009) Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr. Opin. Urol. 19, 232.
37. Abouassaly, R., Lane, B.R., and Jones, J.S. (2008) Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology 71, 573.
38. Fleshner, N. and Klotz, L. (2002) Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology 60, 93.
39. Onik, G., Miessau, M., and Bostwick, D.G. (2009) Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J. Clin. Oncol. 27, 4321.
40. Thompson, I.M., Goodman, P.J., Tangen, C.M., et al. (2003) The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215.
41. Cohen, Y.C., Liu, K.S., Heyden, N.L., et al. (2007) Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 99, 1366.
42. Fleshner, N., Gomella, L.G., Cookson, M.S., et al. (2007) Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp. Clin. Trials 28, 763.
43. D'Amico, A.V., Chen, M.H., Roehl, K.A., et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 351, 125.
44. Parulekar, W.R., McKenzie, M., Chi, K.N., et al. (2008) Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group. Curr. Oncol. 15, 179.
45. Krakowsky, Y., Loblaw, A., and Klotz, L. (2010) Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J. Urol. 184, 131.
46. Dall'Era, M.A., Konety, B.R., Cowan, J.E., et al. (2008) Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112, 2664.
47. Dall'era, M.A., Cowan, J.E., Simko, J., et al. (2010) Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. [Epub ahead of print]
48. Carter, H.B., Kettermann, A., Warlick, C., et al. (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J. Urol. 178, 2359.
49. Tseng, K.S., Landis, P., Epstein, J.I., et al. (2010) Risk stratification of men choosing surveillance for low risk prostate cancer. J. Urol. 183, 1779.
50. Ross, A.E., Loeb, S., Landis, P., et al. (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J. Clin. Oncol. 28, 2810.
51. Ng, M.K., Van As, N., Thomas, K., et al. (2009) Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int. 103, 872.
52. Stattin, P., Holmberg, E., Johansson, J.E., et al. (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J. Natl. Cancer Inst. 102, 950.
53. Wilt, T.J., Brawer, M.K., Barry, M.J., et al. (2009) The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp. Clin. Trials 30, 81.
54. Donovan, J., Hamdy, F., Neal, D., et al. (2003) Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol. Assess. 7, 1.
55. Newcomb, L.F., Brooks, J.D., Carroll, P.R., et al. (2010) Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology 75, 407.
56. Soloway, M.S., Soloway, C.T., Williams, S., et al. (2008) Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 101(2), 165.